Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic Tocilizumab to Prevent CRS With Ramantamig in Relapsed/Refractory Multiple Myeloma
NCT07589634Phase 2Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 10
01
Overview
A Phase 2 trial of tocilizumab in cytokine release syndrome (CRS), sponsored by Janssen Pharmaceutical. Started Jun 2026; status: recruiting.
02
Drugs
tocilizumab
03
Conditions
cytokine release syndrome (CRS)
Beyond the preview
Go deeper on NCT07589634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07589634.